Ionis Pharmaceuticals

Antisense oligonucleotide therapeutics

IONS · Nasdaq · United States

Share price · IONS

$27.39-32.23 (-54.06%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.2M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IONS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026-9.1%
  2. 9 Nov 2026-21.4%
  3. 9 Jul 2026-23.9%
  4. 29 Apr 2026+4.2%
  5. 5 Mar 2026-5.4%
  6. 25 Feb 2026-5.3%

Share of unusual movement by asset

For each asset, the share of IONS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Olezarsen (Tryngolza)
events and moves
1127%
Donidalorsen (Dawnzera)
events and moves
5shown from 8 days
Zilganersen (Zanvastro)
events and moves
5shown from 8 days
Diranersen
events and moves
4shown from 8 days
Sefaxersen
events and moves
3shown from 8 days
Eplontersen (Wainua)
events and moves
2shown from 8 days
Pelacarsen
events and moves
1shown from 8 days
Tofersen (Qalsody)
events and moves
1shown from 8 days
Inotersen (Tegsedi)
events and moves
1shown from 8 days
Ulefnersen
events and moves
1shown from 8 days
Elsunersen
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—18%
Other company news (earnings, financing, releases naming no asset)—23%
Sessions with no dated event—33%

Assets

(20 total)
20Total Assets
6Approved
6Phase 3 / Filed
8Phase 1–2 / Early
16Diseases
Quick filter:
Showing 20 of 20 assets
Target & Modality
Donidalorsen(Dawnzera)
Approved
Prekallikrein (PKK) mRNARNA / oligonucleotide
Hereditary Angioedema
Eplontersen(Wainua)
Approved
Transthyretin (TTR)RNA / oligonucleotide
Transthyretin-Mediated Amyloidosis
Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy
Nusinersen(Spinraza)
Approved
SMN2 pre-mRNARNA / oligonucleotide
Spinal Muscular Atrophy
Olezarsen(Tryngolza)
Approved
APOC3RNA / oligonucleotide
Familial Chylomicronemia SyndromeSevere HypertriglyceridemiaCardiovascular Disease / Dyslipidemia
Hypertriglyceridemia
Tofersen(Qalsody)
Approved
SOD1RNA / oligonucleotide
Amyotrophic Lateral Sclerosis
Zilganersen(Zanvastro)
Approved
GFAP pre-mRNARNA / oligonucleotide
Alexander Disease
Inotersen(Tegsedi)
US approval withdrawn
Transthyretin (TTR)RNA / oligonucleotide
Transthyretin-Mediated Amyloidosis
Transthyretin Amyloidosis with Polyneuropathy
Phase 3
SCN2A (antisense knockdown)RNA / oligonucleotide
Epilepsy
Phase 3
UBE3A-ATS (UBE3A antisense transcript)RNA / oligonucleotide
Angelman Syndrome
Phase 3
Apolipoprotein(a) mRNARNA / oligonucleotide
Atherosclerotic Cardiovascular Disease
Phase 3
Complement factor B (CFB)RNA / oligonucleotide
IgA Nephropathy
Phase 3
FUSRNA / oligonucleotide
Amyotrophic Lateral Sclerosis
Volanesorsen(Waylivra)No recent activity
Phase 3
APOC3 mRNARNA / oligonucleotide
Familial Chylomicronemia SyndromeSevere Hypertriglyceridemia
Phase 2
STAT3 antisense oligonucleotideRNA / oligonucleotide
Non-Small Cell Lung Cancer
Phase 2
MAPT mRNA (RNAi/ASO)RNA / oligonucleotide
Alzheimer's Disease

Upcoming events

(22 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
TonlamarsenPhase 2Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Est. primary completion 2026-12 · NCT07511361 · CT.gov ↗
What to watch
Donidalorsen · DawnzeraPhase 3Hereditary Angioedema
Est. primary completion 2026-12 · NCT05392114 · CT.gov ↗
What to watch
ElsunersenPhase 3Epileptic Encephalopathy, SCN2A Encephalopathy
Est. primary completion 2026-12 · NCT07019922 · CT.gov ↗
What to watch
2027 (6)
March 2027 (1)
Olezarsen · TryngolzaPhase 3Severe Hypertriglyceridemia
Est. primary completion 2027-03 · NCT05681351 · CT.gov ↗
What to watch
June 2027 (1)
Olezarsen · TryngolzaPhase 3Familial Chylomicronemia Syndrome
Est. primary completion 2027-06 · NCT05185843 · CT.gov ↗
What to watch
August 2027 (2)
ObudanersenPhase 3Angelman Syndrome
Est. primary completion 2027-08 · NCT06914609 · CT.gov ↗
What to watch
Tofersen · QalsodyPhase 3Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Est. primary completion 2027-08-07 · NCT04856982 · CT.gov ↗
What to watch
September 2027 (2)
ION775Phase 2Hypertriglyceridemia, Severe Hypertriglyceridemia
Est. primary completion 2027-09 · NCT07604974 · CT.gov ↗
What to watch
Nusinersen · SpinrazaPhase 3Spinal Muscular Atrophy
Est. primary completion 2027-09-24 · NCT05067790 · CT.gov ↗
What to watch
2028 (4)
February 2028 (2)
Olezarsen · TryngolzaPhase 3Familial Chylomicronemia Syndrome
Est. primary completion 2028-02 · NCT05130450 · CT.gov ↗
What to watch
PelacarsenPhase 3Atherosclerotic Cardiovascular Disease (ASCVD)
Est. primary completion 2028-02-03 · NCT06813911 · CT.gov ↗
What to watch
May 2028 (2)
ObudanersenPhase 3Angelman Syndrome
Est. primary completion 2028-05 · NCT07782827 · CT.gov ↗
What to watch
SefaxersenPhase 3Primary IgA Nephropathy
Est. primary completion 2028-05-25 · NCT05797610 · CT.gov ↗
What to watch
2029 (3)
June 2029 (1)
Donidalorsen · DawnzeraPhase 3Hereditary Angioedema (HAE)
Est. primary completion 2029-06 · NCT07298447 · CT.gov ↗
What to watch
August 2029 (2)
Eplontersen · WainuaPhase 3Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Est. primary completion 2029-08 · NCT05071300 · CT.gov ↗
What to watch
Eplontersen · WainuaPhase 3Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Est. primary completion 2029-08 · NCT05667493 · CT.gov ↗
What to watch
2030 (5)
January 2030 (1)
PelacarsenPhase 3Cardiovascular Disease and Lipoprotein(a)
Est. primary completion 2030-01-09 · NCT07517263 · CT.gov ↗
What to watch
March 2030 (1)
PelacarsenPhase 2Aortic Stenosis
Est. primary completion 2030-03-12 · NCT05646381 · CT.gov ↗
What to watch
August 2030 (1)
Olezarsen · TryngolzaPhase 3Familial Chylomicronemia Syndrome
Est. primary completion 2030-08 · NCT07727538 · CT.gov ↗
What to watch
December 2030 (2)
ION337Phase 1/2Dravet Syndrome
Est. primary completion 2030-12 · NCT07531745 · CT.gov ↗
What to watch
PelacarsenPhase 3Atherosclerotic Cardiovascular Disease
Est. primary completion 2030-12-08 · NCT06875973 · CT.gov ↗
What to watch
2032 (1)
March 2032 (1)
ObudanersenPhase 1/2Angelman Syndrome
Est. primary completion 2032-03 · NCT05127226 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(20)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 November 2026ApprovalOlezarsenEuropean Commission approves Tryngolza in severe hypertriglyceridaemia
EU, European Commission · Source ↗
26 October 2026FDA action dateBepirovirsenPDUFA goal date set for bepirovirsen
US, FDA · Source ↗
20 October 2026ApprovalBepirovirsenFDA approves Hibsago (bepirovirsen) for chronic hepatitis B
US, FDA · Source ↗
23 September 2026Topline resultIONIS-FB-LRx (sefaxersen)Phase 3 IMAgINATION (NCT05797610) met its proteinuria primary endpoint at a prespecified interim analysis
Roche · Source ↗
22 September 2026Topline resultUlefnersenFUSION Phase 3 meets primary endpoint
Ionis Pharmaceuticals · Source ↗
22 September 2026FDA action dateZilganersenFDA PDUFA action date set for zilganersen
US, FDA · Source ↗
4 September 2026Topline resultPelacarsenLp(a)HORIZON Phase III topline: primary endpoint not met
Novartis · Source ↗
24 August 2026ApprovalBepirovirsenJapan approves Hibsago (bepirovirsen) for chronic hepatitis B
JP, MHLW · Source ↗
July 2026Topline resultEplontersenPhase 3 CARDIO-TTRansform missed its primary endpoint
14 May 2026Topline resultDiranersenPhase 2 CELIA of diranersen in early Alzheimer's disease did not meet its primary dose-response endpoint
Biogen (announced also by partner Ionis Pharmaceuticals) · Source ↗
28 April 2026Filing acceptedBepirovirsenFDA accepts bepirovirsen NDA for review
US, FDA · Source ↗
28 April 2026Priority reviewBepirovirsenFDA grants priority review for bepirovirsen
US, FDA · Source ↗

The 12 most recent of 20 past events are shown.

Financial reports

Quarterly & interim (21)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$243M—$296M+ $1.6B short-term inv.$110M-$179M operating cash flowreport ↗
View 20 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$268M—$350M+ $1.7B short-term inv.$115M$566M operating cash flowreport ↗
2026-Q1$246M—$173M+ $1.7B short-term inv.$93M-$793M operating cash flowreport ↗
2025-Q4——$372M+ $2.3B short-term inv.$229M-$138M operating cash flowreport ↗
2025-Q3$157M—$338M+ $1.9B short-term inv.$129M-$131M operating cash flowreport ↗
2025-Q2$452M—$297M+ $2.0B short-term inv.—$151M operating cash flowreport ↗
2025-Q1$132M—$264M+ $1.9B short-term inv.$147M-$151M operating cash flowreport ↗
2024-Q4——$242M+ $2.1B short-term inv.$104M-$116M operating cash flowreport ↗
2024-Q3$134M—$335M+ $2.1B short-term inv.$140M-$115M operating cash flowreport ↗
2024-Q2$225M—$294M+ $1.8B short-term inv.$66M-$120M operating cash flowreport ↗
2024-Q1$120M—$349M+ $1.9B short-term inv.$143M-$150M operating cash flowreport ↗
2023-Q4——$399M+ $1.9B short-term inv.$9.3M$33M operating cash flowreport ↗
2023-Q3$144M—$352M+ $1.9B short-term inv.$147M-$109M operating cash flowreport ↗
2023-Q2$188M—$425M+ $2.0B short-term inv.$85M-$97M operating cash flowreport ↗
2023-Q1$131M—$309M+ $2.0B short-term inv.$124M-$134M operating cash flowreport ↗
2022-Q4——$276M+ $1.7B short-term inv.$52M-$200M operating cash flowreport ↗
2022-Q3$160M—$315M+ $1.7B short-term inv.$47M-$24M operating cash flowreport ↗
2022-Q2$134M—$522M+ $1.5B short-term inv.$105M-$18M operating cash flowreport ↗
2022-Q1$142M—$543M+ $1.5B short-term inv.$65M-$32M operating cash flowreport ↗
2021-Q4——$869M+ $1.2B short-term inv.—$204M operating cash flowreport ↗
2021-Q3$133M—$633M+ $1.4B short-term inv.$82M-$56M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$944M$916M$372M+ $2.3B short-term inv.$95M-$269M operating cash flowreport ↗

Ionis Pharmaceuticals reported full-year 2025 revenue of $943.71M, up 33.8% YoY, and R&D spend of $915.62M, up 1.6% YoY. Cash and equivalents were $372.26M, within total cash, cash equivalents and short-term investments of $2.7 billion, and the company reported a net loss of $381.39M.

For 2026, Ionis guided to revenue of $800-$825 million, a non-GAAP operating loss of $500-$550 million, and approximately $1.6 billion in cash, cash equivalents and short-term investments. The company highlighted TRYNGOLZA's first-year net product sales of $108 million, the DAWNZERA launch, an sNDA submission for olezarsen in severe hypertriglyceridemia, and an NDA submission for zilganersen in Alexander disease. Pipeline advances included positive Phase 3 B-Well results for bepirovirsen in chronic hepatitis B, with regulatory filings planned, and anticipated Phase 3 readouts for pelacarsen and eplontersen in 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$705M$902M$242M+ $2.1B short-term inv.$113M-$501M operating cash flowreport ↗
2023-FY$788M$900M$399M+ $1.9B short-term inv.$92M-$308M operating cash flowreport ↗
2022-FY$587M—$276M+ $1.7B short-term inv.$67M-$274M operating cash flowreport ↗
2021-FY$810M$638M$869M+ $1.2B short-term inv.$7.2M$31M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($1.2M), 107 sales ($117.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-10Hayden Michael R · directorOpen-market purchase5,000$29.64$148KForm 4
2026-10-16Swayze Eric · EVP ResearchOpen-market sale53$43.54$2KForm 4
2026-10-16Devers Shannon L. · EVP, Chief Human Resources OfcOpen-market sale1,357$43.54$59KForm 4
2026-10-15Swayze Eric · EVP ResearchOption exercise125——Form 4
2026-10-15Devers Shannon L. · EVP, Chief Human Resources OfcOption exercise2,820——Form 4
2026-10-15Swayze Eric · EVP ResearchOption exercise (derivative)125——Form 4
2026-10-15Devers Shannon L. · EVP, Chief Human Resources OfcOption exercise (derivative)2,820——Form 4
2026-08-31Birchler Brian · EVP, Corp and Development OpsOther (see filing)58$51.31$3KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 490 reporting institutions held 172.6M shares ($12.1B, 103.6% of shares outstanding).

#InstitutionSharesValue
1FMR LLC24,556,637$1.8B
2Capital World Investors21,186,369$1.6B
3BlackRock, Inc.10,442,476$784.1M
4VANGUARD PORTFOLIO MANAGEMENT LLC7,808,902$586.4M
5VANGUARD CAPITAL MANAGEMENT LLC7,118,330$534.5M
6WELLINGTON MANAGEMENT GROUP LLP6,391,816$480.0M
7TWO SIGMA INVESTMENTS, LP5,857,629$439.8M
8GEODE CAPITAL MANAGEMENT, LLC3,984,332$305.2M
9STATE STREET CORP3,995,564$300.0M
10ROYAL BANK OF CANADA3,801,815$285.5M
11JPMORGAN CHASE & CO2,363,567$171.4M
12Tweedy, Browne Co LLC2,275,625$170.9M
13Artisan Partners Limited Partnership2,058,308$154.6M
14BAKER BROS. ADVISORS LP2,047,727$153.8M
15DEERFIELD MANAGEMENT COMPANY, L.P.1,979,669$148.7M